Audentes Therapeutics
San Francisco, US · Founded 2012 · Delaware corporation · 6 known investors
Find your way into Audentes Therapeutics
374 people in our graph share verified history with the Audentes Therapeutics team — schools, employers, funds. One of them is your warm intro.
Scott Billerunlockedknows Matthew R. Patterson · together at Remix Therapeutics (overlapped)
knows the team · via Vor Biopharma
×2knows the team · via SR One Capital Management
×4knows the team · via Genzyme
×3knows the team · via Bowdoin College
knows the team · via Rezo Therapeutics
Founders & leadership
Audentes Therapeutics was founded in 2012 by Matthew Patterson.
MP
Matthew PattersoninFounder · Strategic Advisor2020–2021Venture Partner - US Investments at SR One Capital Management
Board
JS
SS
KP
Kush ParmarBoard director
JL
TW
Thomas WoiwodeBoard director
LG
TS
Thomas SchuetzBoard director
Investors · 6
Reported raises · per SEC filings
Form D private placements$107.5M disclosed across 2 of 3 rounds · 2014–2015
▶$65MraisedOct 2015 · 27 investors · BiotechnologyRule 506(b)
▶$65MraisedOct 2015 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steve SquintoDirector
- Matthew PattersonExecutive Officer, Director
- Jonathan LeffDirector
- Kush ParmarDirector
- Thomas WoiwodeDirector
- Jonathan SilversteinDirector
- Thomas SchuetzDirector
- Louis LangeDirector
- Offering amount
- $65M
- Amount sold
- $65M
- First sale
- Oct 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶Undisclosed amountofferedSep 2015 · 21 investors · BiotechnologyRule 506(b)
▶Undisclosed amountofferedSep 2015 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan SilversteinDirector
- Steve SquintoDirector
- Kush ParmarDirector
- Jonathan LeffDirector
- Matthew PattersonExecutive Officer, Director
- Thomas WoiwodeDirector
- Louis G. LangeDirector
- Thomas SchuetzDirector
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$42.5MraisedDec 2014 · 11 investors · BiotechnologyRule 506(b)
▶$42.5MraisedDec 2014 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas SchuetzDirector
- Kush ParmarDirector
- Matthew PattersonExecutive Officer, Director
- Jonathan SIlversteinDirector
- Thomas WoiwodeDirector
- Jonathan LeffDirector
- Offering amount
- $42.5M
- Amount sold
- $42.5M
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
5 people who came through Audentes Therapeutics went on to found or lead other companies.
Matthew R. PattersonExecutive Officer, DirectorFounded IRIS MEDICINE +1Genine WinslowDirector Research AnalyticsFounded Chameleon Biosciences +1Kush M ParmarBoard Of DirectorsFounded Homology MedicinesLou LangeDirectorFounded CV TherapeuticsSchuetz ThomasBoard of DirectorsFounded Compass Therapeutics
In the news
Frequently asked questions
- Who founded Audentes Therapeutics?
- Audentes Therapeutics was founded by Matthew Patterson in 2012.
- Who are Audentes Therapeutics's investors?
- Audentes Therapeutics's investors include Asset Management Company, RA Capital, venBio Partners, Deerfield Management Company, OrbiMed, Venrock.
- How much funding has Audentes Therapeutics raised?
- Audentes Therapeutics has disclosed $107.5M raised across 2 of its 3 known rounds.
- Where is Audentes Therapeutics headquartered?
- Audentes Therapeutics is headquartered in San Francisco, US.